Psoriasis Vulgaris Pipeline: 45+ Therapies in Development by Pharma Leaders Set to Reshape the Psoriasis Vulgaris Treatment Paradigm | DelveInsight

The psoriasis vulgaris treatment landscape is witnessing robust advancement, spearheaded by biopharmaceutical innovators such as Xencor, Ono Pharmaceutical Co. Ltd, Boehringer Ingelheim, GC Cell Corporation, Soligenix, Cantargia AB, and Huabo Biopharm. While biologics targeting IL-17, IL-23, and TNF-α have become standard care, current R&D is focused on next-generation therapies that aim to improve long-term disease control, enhance patient compliance, and reduce relapse rates. Emerging approaches include topical JAK inhibitors, novel monoclonal antibodies, and orally administered small molecules targeting key immune-modulating pathways.

DelveInsight's "Psoriasis Vulgaris - Pipeline Insight, 2025" delivers a comprehensive analysis of the clinical development landscape, profiling investigational therapies ranging from early-stage research to Phase III trials. The report assesses each candidate's mechanism of action, clinical data, development stage, and market potential.

This pipeline intelligence offers a 360° view of psoriasis vulgaris drug development, segmented by molecule type, route of administration, and development phase. It also explores critical unmet needs, strategic partnerships, regulatory milestones, and potential disruptors poised to redefine the future of psoriasis vulgaris management.

Key Takeaways from the Psoriasis Vulgaris Pipeline Report
• DelveInsight's psoriasis vulgaris pipeline analysis depicts a strong space with 40+ active players working to develop 45+ pipeline drugs for psoriasis vulgaris treatment.
• The leading psoriasis vulgaris companies include Xencor, Ono Pharmaceutical Co. Ltd, Boehringer Ingelheim, GC Cell Corporation, Soligenix, Cantargia AB, Huabo Biopharm, Huaota Biopharmaceuticals, Bio-Thera Solutions, Hangzhou Highlightll Pharmaceutical, Sanofi, Meiji Pharma, and others are evaluating their lead assets to improve the psoriasis vulgaris treatment landscape.
• Key psoriasis vulgaris pipeline therapies in various stages of development include XmAb564, BAT-2306, ONO-4685, BI 765250, CT303, SGX302, CAN10, HB0017, HOT-3010, TLL018, SAR441566, ME3183, and others.
• In March 2025, LEO Pharma announced the initiation of a Phase III, national, multi-center, 4-week, prospective, randomized, controlled, parallel-group, open-label trial in Japan. The study compares LEO 90100 foam to DOVOBET® ointment-both formulations containing calcipotriol hydrate and betamethasone dipropionate-in Japanese patients with psoriasis vulgaris.
• In March 2025, Biocon Biologics Ltd. announced successful results from a pivotal Phase III, randomized, double-blind, multicenter study comparing YESINTEKTM (biosimilar to Ustekinumab) with the reference product STELARA (Ustekinumab) in adults with moderate to severe chronic plaque psoriasis (PsO).
• In December 2024, Celltrion announced that the FDA approved STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), for subcutaneous injection or intravenous infusion. It is approved for adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.
• In September 2024, UCB announced that the FDA approved BIMZELX® (bimekizumab-bkzx) for adults with active psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS). BIMZELX is the first therapy to selectively inhibit both IL-17A and IL-17F-two key drivers of inflammation. This expands on its initial U.S. approval in October 2023 for moderate-to-severe plaque psoriasis.

Request a sample and discover the recent breakthroughs happening in the psoriasis vulgaris pipeline landscape here: https://www.delveinsight.com/report-store/psoriasis-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Vulgaris Overview
Psoriasis vulgaris, also known as chronic plaque psoriasis, is the most prevalent form of psoriasis, accounting for 80-90% of all cases. It is a chronic, immune-mediated skin disorder characterized by raised, red plaques covered with silvery-white scales, commonly appearing on areas prone to trauma or irritation such as the elbows, knees, and scalp. Though it presents in various clinical forms-including guttate, pustular, flexural, and erythrodermic-plaque psoriasis remains the hallmark presentation with well-demarcated, scaly, erythematous lesions, especially on extensor surfaces.

The disease is not curable but is manageable with timely medical intervention. It involves a complex interplay of genetic, immunologic, and environmental factors. Psoriasis pathogenesis is marked by accelerated keratinocyte proliferation, abnormal skin cell differentiation, and chronic inflammation. Environmental triggers like infections, stress, and certain medications, such as lithium, NSAIDs, antimalarials, ACE inhibitors, and ARBs, can induce or exacerbate the condition in genetically susceptible individuals.

Diagnosis is typically clinical, based on skin, scalp, and nail examination, along with the patient's medical and family history. In rare cases, a skin biopsy may be performed to confirm the diagnosis or rule out other dermatologic conditions.

Find out more about psoriasis vulgaris medication @ https://www.delveinsight.com/report-store/psoriasis-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Vulgaris Treatment Analysis: Drug Profile
BAT2306: Bio-Thera Solutions
BAT2306 is a biosimilar of Cosentyx (secukinumab), an IL-17A inhibitor approved for conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). In China, its approval covers plaque psoriasis and AS. IL-17A, primarily secreted by Th17 cells, as well as neutrophils, mast cells, and other T cells, stimulates the production of pro-inflammatory cytokines and activates various immune cells, including neutrophils, macrophages, epithelial cells, and fibroblasts. BAT2306 is currently in Phase III clinical development for treating plaque psoriasis.

SGX302: Soligenix
SGX302 is a novel photodynamic therapy in development for psoriasis vulgaris. It utilizes synthetic hypericin, a highly photoactive compound, formulated as a topical ointment and activated by visible fluorescent light. Upon application, hypericin is absorbed by skin cells and, when exposed to light, becomes therapeutically active. SGX302 is currently being evaluated in Phase II clinical trials for psoriasis vulgaris.

CAN10: Cantargia AB
Cantargia's CAN10 is a monoclonal antibody targeting IL1RAP, a co-receptor involved in transmitting inflammatory signals from IL-1, IL-33, and IL-36. By blocking IL1RAP, CAN10 can inhibit multiple inflammatory pathways simultaneously, offering a potentially more comprehensive therapeutic effect than drugs targeting individual pathways. CAN10 is currently in Phase I clinical trials for the treatment of psoriasis vulgaris.

Learn more about the novel and emerging psoriasis vulgaris pipeline therapies here: https://www.delveinsight.com/report-store/psoriasis-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Vulgaris Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Psoriasis Vulgaris Pipeline Report
• Coverage: Global
• Key Psoriasis Vulgaris Companies: Xencor, Ono Pharmaceutical Co. Ltd, Boehringer Ingelheim, GC Cell Corporation, Soligenix, Cantargia AB, Huabo Biopharm, Huaota Biopharmaceuticals, Bio-Thera Solutions, Hangzhou Highlightll Pharmaceutical, Sanofi, Meiji Pharma, and others.
• Key Psoriasis Vulgaris Pipeline Therapies: XmAb564, BAT-2306, ONO-4685, BI 765250, CT303, SGX302, CAN10, HB0017, HOT-3010, TLL018, SAR441566, ME3183, and others.

Dive deep into rich insights for drugs used for psoriasis vulgaris treatment; visit: https://www.delveinsight.com/report-store/psoriasis-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Psoriasis Vulgaris Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Psoriasis Vulgaris Pipeline Therapeutics
6. Psoriasis Vulgaris Pipeline: Late-Stage Products (Phase III)
7. Psoriasis Vulgaris Pipeline: Mid-Stage Products (Phase II)
8. Psoriasis Vulgaris Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.